AAMAC Patient and Caregiver Survey

AAMAC is developing a submission for the pan-Canadian Oncology Drug Review (pCODR) for (orally administered/tablets) decitabine and cedazuridine (INQOVI) for the treatment of patients with Myelodysplastic Syndrome (MDS).

We are specifically seeking input from patients with experience with treatments for MDS including oral decitabine (INQOVI).

Your insights and experience will help guide the pan-Canadian Oncology Drug Review – an evidence-based, cancer drug review process designed to inform Canada’s provinces and territories* in guiding their drug funding decisions.

The survey can be found at

This survey will take approximately 12 minutes to complete. We ask that you complete the survey by October 1.

If you have any questions about this survey, please write to us at info@aamac.ca and include “Patient and Caregiver Survey” in the subject line of the email.

Thank you for your participation!